Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2019
The total study duration was 24 weeks which included a screening period of 4 weeks, a treatment period of 16 weeks, and a follow‐up period of up to 4 weeks. Participants who completed the Week 16 visit were proposed to be enrolled in a long‐term extension safety and efficacy study to assess safety, tolerability and efficacy of SAR442168.
Epistemonikos ID: be6a17ef050a685fdc8a197de6466c5ad760097a
First added on: Mar 31, 2022